acenocoumarol and Adenocarcinoma

Drug interactions can cause many clinical problems, particularly when the drugs are administered in combination with anticancer agents.. A patient required two hospitalizations due to risk of bleeding with altered INR probably due to an interaction between gefitinib and acenocoumarol, which resulted in the potentiation of the effect of the latter and acenocoumarol dose adjustment was needed. A causality assessment between the drug-drug interaction and the augmented INR was conducted according to Naranjo algorithm and was classified as a definite adverse drug reaction.. Patient's management recommended is to closely monitor for changes in the effects of coumarin derivatives, if administered concomitantly with antineoplasic agents.

Topics: Acenocoumarol; Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Heart Failure; Humans; International Normalized Ratio; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines

Topics: Acenocoumarol; Adenocarcinoma; Anticoagulants; Biopsy, Needle; Colonoscopy; Epinephrine; Erythrocyte Transfusion; Gastrointestinal Hemorrhage; Heart Valve Prosthesis; Hemostatics; Heparin, Low-Molecular-Weight; Humans; Hypotension; Male; Polidocanol; Polyethylene Glycols; Prostate; Prostatic Neoplasms; Rectal Diseases; Rectum; Sclerosing Solutions

We compared the effects of various potential effector cells of syngeneic or allogeneic origin on the take of a spontaneous adenocarcinoma (SP4) and Lewis lung (LL) carcinoma. As reported earlier, syngeneic resident (non-activated) peritoneal cells (PC) did not inhibit the take of these tumours. On the contrary, transfer of resident PC from allogeneic donors suppressed the tumour take. Syngeneic and allogeneic PC activated by poly I:C or by a combination of indomethacin, poly I:C and Syncumar ("combined treatment") inhibited the tumour take to a similar extent. Syngeneic spleen cells (from untreated mice or from donors underwent "combined treatment") did not inhibit the take of Lewis lung tumour. Transfer of activated allogeneic spleen cells resulted in a stronger inhibition of tumour take than the transfer of resident allogeneic spleen cells.

Topics: Acenocoumarol; Adenocarcinoma; Animals; Carcinoma; Indomethacin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Peritoneal Cavity; Poly I-C; Spleen; Transplantation, Homologous; Transplantation, Isogeneic

We studied the properties of activated peritoneal cells (PC) inhibiting the take of SP4 spontaneous adenocarcinoma and Lewis lung carcinoma in syngeneic mice. Treatment of the poly I:C activated PC from Balb/c mice suppressing the take of SP4 tumour with anti-asialo GM1 antibody and complement before transfer did not affect their tumour-inhibitory potential. PC from Balb/c nude mice treated with poly I:C also inhibited the take of SP4 tumour. Spleen cells from untreated or poly I:C treated Balb/c and Balb/c nude mice, however, did not inhibit the take of SP4 adenocarcinoma. Treatment of peritoneal cells activated by a combination of poly I:C, indomethacin and Syncumar (referred to as "combined treatment") with anti-asialo GM1 antibody and complement could not, or could only partly abolish their tumour-inhibitory potential. The cells mediating the suppression of the take of Lewis lung tumour proved to be Thy-1,2+/-, Lyt-1-, Lyt 2.2- cells. We conclude that the activated peritoneal cells inhibiting the take of SP4 adenocarcinoma and Lewis lung tumour are different from NK cells, NC cells and LAK cells and represent a distinct antitumoural effector cell population.

Topics: Acenocoumarol; Adenocarcinoma; Animals; Antibodies; Carcinoma; Complement System Proteins; Female; G(M1) Ganglioside; Glycosphingolipids; Indomethacin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Peritoneal Cavity; Poly I-C

Haemorrhagic infarction of the breast induced by anticoagulant therapy is rare and has been infrequently reported in the literature. The following report illustrates such a case in which there was development of massive haemorrhagic infarction of the breast during treatment with nicoumalone for deep venous thrombosis after an operation for carcinoma of the colon.

Topics: Acenocoumarol; Adenocarcinoma; Aged; Breast; Colonic Neoplasms; Female; Heparin; Humans; Infarction; Postoperative Complications

Topics: Acenocoumarol; Adenocarcinoma; Adult; Anticoagulants; Bronchial Neoplasms; Female; Humans; Leg; Necrosis; Thrombophlebitis